Vanguard Global Advisers’s Moleculin Biotech MBRX Stock Holding History

Vanguard Global Advisers’s Portfolio MBRX Stock Details MBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-24	Closed	-$55	–	3703
2026 Q1	$55	Buy	+24	New	+$79	﹤0.01%	3679

Other funds holding MBRX

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Rockefeller Capital Management New York $65.2B AUM 31.44% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Global Advisers's MBRX Position: Q2 2026 in Review

Vanguard Global Advisers sold out of Moleculin Biotech (MBRX) in Q2 2026, closing a stake of 24 shares — an estimated $55 sold.

Vanguard Global Advisers first reported a position in MBRX in Q1 2026 and held it in 1 quarter. The position peaked at $55 in Q1 2026. 17 funds tracked by Wall St. Rank hold MBRX as of Q2 2026.

Vanguard Global Advisers reported no remaining Moleculin Biotech position as of Q2 2026 after selling out during the quarter.
Vanguard Global Advisers sold 24 Moleculin Biotech shares in Q2 2026, an estimated $55.
Vanguard Global Advisers first reported a position in Moleculin Biotech in Q1 2026 and held it in 1 quarter.
Vanguard Global Advisers's Moleculin Biotech position peaked at $55 in Q1 2026.
17 funds tracked by Wall St. Rank held Moleculin Biotech as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.